Clinical Trial Detail

NCT ID NCT02643550
Title Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Innate Pharma

oral cavity cancer

hypopharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma


Cetuximab + Monalizumab

Age Groups: adult

No variant requirements are available.